Share this page!

Value Educator Profile picture
Twitter logo
Jul 30 β€’ 13 tweets β€’ 4 min read
#PiramalPharma Q3 Concall highlights πŸ’ŠπŸ’Š

Like & Share for better reach !

The demerger of Piramal enterprises is expected to be completed by Q3 FY2023

Q1 FY2023 Performance

Pharma Revenues Image
CDMO :
Q1 FY23 Revenue grew 8% YoY
Despite the global challenges in biotech funding, company is witnessing high RFP activity from existing and new clients according the management

Major Issues in the CDMO business
1. Significant attrition at overseas site during pandemic Image
2. Customer order deferrals
This is coupled with several execution and supply chain challenges

Capacity expansion in niche capabilities ( Previously Planned CAPEX: US$157mn growth capex underway):

- Inaugurated new API plant in Aurora, Canada
- Upgraded Oral Solid Dose
capabilities with new production block at Pithampur, India
- Unlocked API manufacturing capacities through various operational excellence tools in Digwal, India
CHG
Q1 FY23 Revenue grew 10% YoY, driven by
- Strong Inhaled Anesthesia sales in the US
- Executed Sevoflurane contract extensions with major integrated delivery networks and won multiple tenders in EU and across other geographies
- Facing some supply constraints from third Image
party CMOs which Piramal is in the process of remediating
- Intrathecal Portfolio in the US continued to command leading market share despite increased competition from generics according to the management
- Launched Prefilled Syringe (PFS) in Italy
ICH
ICH business continued its growth momentum with Q1FY23 revenue growth of 17% YoY driven by
- Strong performance in power brands, contributing 57% to the FY22 revenues
- Launched 7 new products in Q1 FY23
- New products launched since Apr’20 Image
contribute to 15% of ICH sales in FY22

Management expects major part of the Pharma business to be in the second half of the financial year which is in line with their historical incidences

Short to Medium term guidance : Refrained due to volatility and
execution related challenges.

Long term guidance : Mid-High teens sustained.

Expansion of CDMO facility at Canada has given additional capacity of 35% and management expects to utilize this over the next couple of years
The expansions of facilities that Piramal is doing now and what they have planned for the future is keeping in mind what kind of opportunities they’ll come across in terms of commercialization of Phase III molecules and catering to customer requirements
Capex plan for FY23&24:

$200mn/annum
Mid term: Expansion of HPAPI at Riverview, ADC at Grangemouth, API facilities at India and Sterile potent injectables at Lexington
Register to model portfolio to watch detailed video on #piramalpharma

Link : valueeducator.com/advisory/

CDMO :

β€’ β€’ β€’

Missing some Tweet in this thread? You can try to force a refresh
γ€€

Keep Current with Value Educator

Value Educator Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @ValueEducator

Value Educator Profile picture
Aug 1
#LaxmiOrganics Q1 2023 Concall Highlights

Like & retweet for better reach !

1. Despite the market volatility and the inflationary pressure seen across the globe the Speciality Intermediates (SI) business saw growth both in the exports & in the contribution margins.
2. Commissioned a new plant for SI supplies to an agrochemical major. Most of this capacity is already contracted.

3. The AI business saw QoQ improvement in EBITDA Margins and exports also grew very well. Almost 40% of the revenues of the company came from exports in the Q1FY23.
4. The company optimizes procurement between imports and local supplies to support the margin expansion in the AI business that was aided also by the softening of petrochemicals and acetic acid prices internationally.

5. The quarterly EBITDA at 104 Crores resulted in an
Read 25 tweets
Value Educator Profile picture
Jul 28
#LaurusLabs Q1 FY23 concall highlights πŸ’ŠπŸ’Š

Like & Retweet for better reach !

1. Revenue for the quarter was β‚Ή1539 Cr (20% growth YoY). The EBITDA margin was 29.5% for the quarter despite inflationary pressures.

2. They saw significant growth in their CDMO business
(196% growth YoY, 60% growth QoQ) which helped offset the muted performance of the ARV business.

3. RM prices remain elevated due to the geopolitical situation and the Covid lockdown in China. But they are expecting gradual decrease in RM prices during the year
4. They are confident of achieving the aspirational target of $1 billion in revenue which will be supported by several approvals during the year.

5. With respect to their ARV business in LMIC markets - the demand was soft but the major issue is that the pricing has been largely
Read 18 tweets
Value Educator Profile picture
Jul 28
Detailed Thread on #apollopipes

Like & Retweet for better reach !

Topics Covered :

1. Company overview
2. Management
3. APL Apollo Tubes Ltd
4. Products
5. Margins
6. Plants
7. Distribution
8. Marketing
9. Revenue mix
10. Company’s Key Focus Areas
11. Future Capex
12. Financials
13. EBITDA Margins

1. Company Overview
Apollo Pipes is among the top 10 leading piping solution providing companies in India. Headquartered at Delhi, the Company enjoys strong brand equity in the domestic markets. With more than three decades of experience
in the Indian PVC Pipe Market, Apollo Pipes holds a strong reputation for high quality products and an extensive distribution network.
Read 36 tweets
Value Educator Profile picture
Jul 28
#SuvenPharma Annual Report 2022 Key Takeaways πŸ’ŠπŸ’Š

Like & retweet for better reach !

1. They had a great performance in FY22. They had initially given a guidance of 10-15% growth in revenues and ended the year with 47% growth in topline.
The EBITDA margin was above 50% for the year despite inflationary pressure.

2. A major part of the growth came from the Specialty Chemicals segment. Revenue for this vertical grew by 51% YoY due to increased volumes. They saw good volume offtake for the 1st commercialized
molecule which is now generic. But the partner developed a robust life cycle management which generated good volumes.

3. There was also a commercialization of a 3rd molecule in this segment which helped increase volumes. They currently have 1 more molecule in development
Read 16 tweets
Value Educator Profile picture
Jul 27
#apollopipes Q1 23 Concall Highlights

Like & Retweet for better reach !

1. Revenue in Q1 FY23 grew by 59% to 218.9 crs from 137.6 crs in Q1 Fy22 but down 11.5% sequentially from 247.5 crs. Volume grew 38% to 14406MT from 10200MT in Q1 FY22.
2. EBITDA was 20.0 crs as against 17.4 crs y-o-y but dropped from 28.4 cr in previous quarter. Margin also dropped to 9.2% from 11.5% q-o-q. EBITDA per tonne dropped to 14000 per tonne from 17500 per tonne. This drop was because of drop in pvc prices.
Company is targeting 20000 EBITDA per tonne in next two years.
3. Growth looks robust y-o-y basis because of low base last year but weak sequentially because
of massive correction in PVC prices. This created uncertainty among channel partners who went into destocking mode.
Read 12 tweets
Value Educator Profile picture
Jul 27
#FinolexPipes Q1 23 Concall Highlights

Like and Retweet for better reach !

1. Total revenue registered a y-o-y growth of 23% to Rs. 1,190 Cr from Rs. 965 Cr, but down
25% q-o-q from 1595 cr.
2. Degrowth in EBITDA was 40% to 126cr in Q1 23 from 210 cr in Q1 22. Margins also dropped
to 11% from 22%. Reasons for fall in EBITDA were because of Weak agri demand and
inventory losses due to fall in PVC prices.
3. PVC Pipes & Fittings volume grew 29% y-o-y to 71,960 MT and for PVC Resin volume registered a y-o-y growth of 25% to 62,746 MT. Volume for CPVC was 3600 MT with revenue of about 150 crores.
Read 13 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(